沙利度胺辅助治疗新型冠状病毒(COVID-19)感染者的循证医学思考与可行性探索  

Feasibility of Adjuvant Therapy with Thalidomide in the Treatment of Patients Infected with Novel Coronavirus (COVID-19) According to Evidence-Based Medicine

作　　者：徐晓 梁景耀[1,2] 叶瑞贤 郑捷[3] 张锡宝 XU Xiao;LIANG Jingyao;YE Ruixian;ZHENG Jie;ZHANG Xibao(Institute of Dermatology,Guangzhou Medical University,Guangzhou 510095,China;Department of Dermatology,Guangzhou Institute of Dermatology,Guangzhou 510095,China;Department of Dermatology,Ruijing Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)

机构地区：[1]广州医科大学皮肤病研究所,广东广州510095 [2]广州市皮肤病防治所,广东广州510095 [3]上海交通大学瑞金医院皮肤科,上海200025

出　　处：《中国皮肤性病学杂志》2020年第6期611-616,共6页The Chinese Journal of Dermatovenereology

摘　　要：新型冠状病毒(COVID-19)的发现以及其快速传播是对全国甚至全球公共卫生的挑战。如何有效控制传播,快速治愈感染者已经成为目前国家乃至全世界的抗疫焦点。目前对于新型冠状病毒感染的肺炎尚无明确有效的抗病毒药物,对患者均采用一般对症支持治疗,对于危及生命的重症肺炎患者使用糖皮质激素存在争议,临床急需更为有效的治疗药物。沙利度胺具有抗炎、抗纤维化、抗血管新生、免疫调节等多种作用,而无"免疫抑制剂"的副作用,在临床应用于上呼吸道感染所致的肺炎、肺损伤及肺纤维化等疾病的治疗,有效且安全。基于现有关于沙利度胺的基础研究和循证医学经验,探索沙利度胺辅助治疗新型冠状病毒重度感染者的肺炎及相关肺损伤,可为COVID-19重症感染者的治疗提供新的诊疗思路。The emergence of novel coronavirus 2019(COVID-19) and its rapid spread poses critical challenges to public health in China and in the world.How to effectively control the spread and quickly cure the infection has become the focus.Currently,there is no definite effective antiviral drug for pneumonia caused by COVID-19 infection.Patients are treated with general support and symptomatic therapy,however,the application of glucocorticoids in life-threatening severe pneumonia is still controversial.Thus,more effective clinical drugs are urgently needed.Thalidomide has been widely used in the treatment of pneumonia caused by upper respiratory tract infection,lung injury and pulmonary fibrosis for its anti-inflammatory,anti-fibrotic,anti-angiogenesis,immunomodulation effects with good safety but with no side effects of "immunosuppressant".Therefore,the exploration of adjuvant therapy with thalidomide in the treatment of novel coronavirus infection based on the preclinical research available and clinical experience from evidence-based medicine can provide new treatment avenues for the those severe cases with COVID-19 infection.

关 键 词：新型冠状病毒 沙利度胺 疗效 循证医学 

分 类 号：R563.1[医药卫生—呼吸系统]